The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha ...
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Novo Nordisk India team fears losing competitive edge to Eli Lilly Novo's Wegovy and Lilly's Mounjaro are GLP-1 receptor agonists India's obesity rates rising, increasing demand for weight-loss ...
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47 per cent more weight than those who were given ...